Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review.

@article{Ferreira2012TherapeuticTO,
  title={Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review.},
  author={Anderson Jos{\'e} Ferreira and Michael Bader and Robson Augusto Souza Santos},
  journal={Expert opinion on therapeutic patents},
  year={2012},
  volume={22 5},
  pages={567-74}
}
INTRODUCTION The renin-angiotensin system (RAS) is a main therapeutic target for cardiovascular diseases. Within the last two decades, novel components of the RAS have been discovered, opening new opportunities to interfere with its activity. Angiotensin(Ang)-(1-7) is synthesized by angiotensin-converting enzyme 2 (ACE2), and interacts with the G-protein-coupled receptor Mas. The axis formed by ACE2/Ang-(1-7)/Mas represents an endogenous counter regulatory pathway within the RAS. AREAS… CONTINUE READING